Health inequalities and cystic fibrosisBMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4818 (Published 23 August 2011) Cite this as: BMJ 2011;343:d4818
- David Taylor-Robinson, Medical Research Council population health scientist1,
- Michael S Schechter, associate professor2
- 1Department of Public Health and Policy, University of Liverpool, Liverpool L69 3GB, UK
- 2Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, USA
Cystic fibrosis is the most common serious inherited disease in white populations. Intensive support from family and healthcare services is needed from the time of diagnosis onwards, and most patients die prematurely from respiratory failure. Survival has dramatically improved over successive birth cohorts, such that British children born in the 21st century will have a median survival of over 50 years.1 However, disease progression and survival still vary greatly, mostly as a result of social and environmental, rather than genetic, determinants.2 It has been known for more than 20 years that people with cystic fibrosis from socioeconomically disadvantaged backgrounds die younger than those in more advantaged positions.3
In a linked observational study (doi:10.1136/bmj.d4662), Barr and colleagues used death registration data in England and Wales to show that this socioeconomic divide in premature mortality in cystic fibrosis has persisted with no substantial narrowing for over four decades.4 They also show that female patients continue to die at a younger age than men. What can we learn from this, and what are the implications …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.